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This study was undertaken to determine in vivo permeability coeﬃcients for ﬂuoroquinolones and to assess its correlation with
the permeability derived using reported models in the literature. Further, the aim was to develop novel QSPR model to predict
corneal permeability for ﬂuoroquinolones and test its suitability on other training sets. The in vivo permeability coeﬃcient
was determined using cassette dosing (N-in-One) approach for nine ﬂuoroquinolones (norﬂoxacin, ciproﬂoxacin, lomeﬂoxacin,
oﬂoxacin, levoﬂoxacin, sparﬂoxacin, peﬂoxacin, gatiﬂoxacin, and moxiﬂoxacin) in rabbits. The correlation between corneal
permeability derived using in vivo studies with that derived from reported models was determined. Novel QSPR-based model
was developed using in vivo corneal permeability along with other molecular descriptors. The suitability of developed model was
tested on β-blockers (n = 15). The model showed better prediction of corneal permeability for ﬂuoroquinolones (r2 > 0.9) as
well as β-blockers (r2 > 0.6). The newly developed QSPR model based upon in vivo generated data was found suitable to predict
corneal permeability for ﬂuoroquinolones as well as other sets of compounds.
1.Introduction
Topical route is the oldest and convenient mode of drug
administration for ophthalmic disorders. However, several
precorneal factors such as lacrimal secretion (tear turn over
and reﬂux tearing), tear protein binding, pH, shorter contact
time, and other corneal constraints limit drug penetra-
tion [1]. Moreover, presence of various uptake and eﬄux
transporters in cornea also reposted to further complicate
the ocular bioavailability [2]. Therefore, developing drug
speciﬁcally for ophthalmic use is of paramount importance.
Conventionally, the drugs intended for oral admin-
istrations have been developed in consideration of their
physicochemical properties. This enables to enhance the
pharmacokinetic properties, eﬃcacy and reduces the toxicity
of lead compound. In drug discovery exploitation of in silico
techniques to expedite the process of lead optimization in
drug discovery is rampant. Among such techniques, Quan-
titative Structure Property Relationship (QSPR) approach
correlates the biological activity of a molecule with its
physicochemical properties through variety of descriptors.
In recent years, QSPR approach has been exploited for
the development of models to predict penetration of drugs
across physiological barriers such as CNS, blood, and
intestinal [3].
The drugs used for ophthalmic indications are arbitrarily
developed from the oral or systemic indications, rather
than systematically ocular speciﬁc studies. To date, very few2 Journal of Biomedicine and Biotechnology
drugs have been designed, developed, and studied for ocular
speciﬁc use. However, the ocular pharmacokinetics of a drug
is known to be diﬀerent and complicated compared to any
other indications [4] .T h u s ,i nt h i sc o n t e x tad r u gi n t e n d e d
for oral use is expected to behave diﬀerently when used
empirically for the topical application. As physicochemical
properties such as lipophilicity, molecular size, charge,
degree of ionization, solubility, and pH, aﬀect the rate and
extent of corneal permeability [5].
In ophthalmology, ﬂuoroquinolones are most widely
used antimicrobial agents. These agents were initially dis-
covered, designed, and developed for systemic infections
and further extended for ophthalmic use. Their broad-
spectrum activity, bactericidal property, better ocular pene-
tration, and relative safety embark its use in ophthalmology.
Most of the ﬂuoroquinolones for topical use lack regress
understanding of their corneal penetration, residence time,
requiredspectrum,optimumfrequencyofusage,andcorneal
toxicity despite of their widespread use in ophthalmics [6].
Therefore, an emphasis on QSPR strategy to optimize ocular
pharmacokineticpropertiesalongwithantimicrobialeﬃcacy
is desirable [7].
Previously reported QSPR models to predict corneal
permeability for congeneric and noncongeneric drugs have
been developed based upon in vitro studies. A weak corre-
lation is reported to exist between the in vitro and in vivo
studies [8, 9]. Eventually their applicability of these models
to predict in vivo corneal penetration remains unclear.
In present study we developed novel QSPR based in silico
model to predict corneal permeability for ﬂuoroquinolones
based upon in vivo generated permeability coeﬃcient along
with molecular descriptors. The applicability of previously
reported models based upon in vitro data to predict corneal
permeability for ﬂuoroquinolone was also studied. Further-
more, the generated QSPR model was evaluated for its
aptness using the other training sets (β-blockers).
2.MaterialsandMethods
2.1. Chemicals. Pure samples of norﬂoxacin, ciproﬂoxacin
HCl, gatiﬂoxacin, and lomeﬂoxacin HCl were generously
gifted by Dr. Reddy Labs (Hyderabad, India), Lupin Labs
(Pune, India), Sun Pharmaceuticals (Mumbai, India), and
Organics Ltd., (Hyderabad, India), respectively. Gratis sam-
ples of oﬂoxacin, peﬂoxacin mesylate, and sparﬂoxacin were
obtained from Cipla Ltd., (Mumbai, India). Moxiﬂoxacin
and levoﬂoxacin were obtained as a generous gift from
Capital Pharma (Baddi, India). Other chemicals used in the
study were of analytical grade and procured from standard
drug companies.
2.2. Preparation of the Cocktail Formulations. A total of nine
ﬂuoroquinolones (Table 1) were randomly divided into 2
groups wherein, group A consists of oﬂoxacin, sparﬂoxacin,
peﬂoxacin mesylate, and gatiﬂoxacin and group B con-
sists of norﬂoxacin, ciproﬂoxacin HCl, lomeﬂoxacin HCl,
levoﬂoxacin, and moxiﬂoxacin. In both groups, individual
ﬂuoroquinolones were dissolved at concentration of 0.1%.
Thus, the total ﬂuoroquinolones concentration in group A
and group B were 0.4% and 0.5%, respectively. Sterile boric
acid (1.9% w/v) in water was used as the aqueous media
andtheﬁnalformulationswereﬁlteredusing0.22μﬁlterand
autoclaved further before use.
2.3. In Vivo Transcorneal Permeation of Fluoroquinolones
Using Cassette Dosing (N-in-One). Study protocol and
experimental procedures were approved by the Institutional
Animal Ethics Committee of All India Institute of Medical
Sciences (AIIMS), New Delhi, India. New Zealand albino
rabbits of either sex (1.5–2.0kg) were obtained from Central
Animal Facility, AIIMS. Animals were housed at standard
laboratory conditions temperature-controlled room at 24 ±
2◦C and humidity 55 ± 15% and given food and water ad
libitum. All experiments were performed in accordance to
the Association for Research in Vision and Ophthalmology
(ARVO) statement for the use of animals in ophthalmic and
vision research.
The sterile cocktail formulations of group A and group
B were individually instilled (50μL) on the lower fornix of
rabbiteyes(n = 4)withthehelpofacalibratedmicropipette.
Aqueous paracentesis was performed under the inﬂuence of
topical anesthesia at 5, 15, 30, 60, 120, and 240min after the
instillation of cocktail formulation. For each time point, a
volume amounting to 50μL of aqueous humor was aspirated
through the corneal surface. The aqueous humor samples
obtainedwerestoredat −80◦CuntilquantiﬁcationbyHPLC.
2.4. Quantiﬁcation of Fluoroquinolones in Aqueous Humor
Using HPLC. A Thermo Finnigan (Thermo Electron Cor-
poration, USA) HPLC equipped with degasser, quater-
nary pump, autosampler, and PDA detector was employed
for quantiﬁcation of ﬂuoroquinolones in samples. In the
chromatographic quantiﬁcation, analytical separation was
performed using a C18 Symmetry Shield column (4.6 ×
150mm, 5μm, Waters, USA) under a gradient ﬂow of
methanol, acetonitrile, and potassium phosphate buﬀer
(20mM, pH 2.5) at diﬀerent ratio and time. For each spiked
compound an external calibration curve was plotted and the
analyte’s spectra was assessed by matching them with custom
made PDA spectra of inbuilt library of Chromquest version
4 (Thermo Electron Corporation, USA).
Samples were deproteinized with pure acetonitrile (ratio
of 1:2v/v), vortexed, and centrifuged at 3500g for 10min.
Thesupernatantwasvacuumconcentratedat40◦Cforastip-
ulated time. The dried concentrate was reconstituted with
100μL mixture of water and acetonitrile (1:1), and 20μLo f
the obtained supernatant was injected for quantiﬁcation.
2.5.ApplicabilityofReportedModelstoPredictInVivoCorneal
PermeabilityforFluoroquinolones. Availableliteraturereveals
existence of two models correlating the corneal perme-
ability of compounds with their physiochemical properties.
Therefore, present study evaluated the suitability of these
reported models to predict in vivo corneal penetration for
ﬂuoroquinolones.
2.5.1. Evaluation of Model 1 Reported by Yoshida and Topliss.
The ﬁrst model reported by Yoshida and Topliss [10]Journal of Biomedicine and Biotechnology 3
Table 1: Structures of various ﬂuoroquinolones used in the study.
X N R
O
O
O
H
H
F
H
H
1 2
3
4 5
6
7 8
Compound X R1 R5 R7
Norﬂoxacin C C2H5 H HN N
Ciproﬂoxacin C c-C3H5 H HN N
Lomeﬂoxacin C-F C2H5 H
HN N
Me
Oﬂoxacin Fused C-1-8 (O) Cyclic ring H N
N
H3C
Levoﬂoxacin Fused C-1-8 (O) Cyclic ring H N
N
H3C
Sparﬂoxacin C-F c-C3H5 NH2 HN
N
H3C
CH3
Peﬂoxacin C C2H5 H N MeN
Gatiﬂoxacin –C–OCH3 c-C3H5 H
HN N
Me
Moxiﬂoxacin –C–OCH3 c-C3H5 H
HN
N
H
H4 Journal of Biomedicine and Biotechnology
was based upon two molecular descriptors, ΔlogP and
logD to predict corneal permeability coeﬃcient (logPC).
Algorithm(1)isproposedtopredictcornealpermeabilityfor
noncongeneric compounds
logPC =− 0.404(± 0.114)ΔlogP +0 .141(± 0.090)logD
−3.862(± 0.451),
(1)
wherein logPC denotes permeability coeﬃcient, ΔlogP
expresses the diﬀerence between the octanol-water partition
coeﬃcients (logPoctanol) and alkane-water partition coeﬃ-
cients (logPalkane), and logD denotes dissociation constant
As reported, ΔlogP was calculated using LOGPSTAR
software in training sets of 32 diverse noncongeneric com-
pounds including steroids and β-blockers. Since LOGPSTAR
was currently unavailable and obsolete. Therefore, experi-
mentally derived ΔlogP was used for all ﬂuoroquinolones.
ΔlogP was derived as the diﬀerence in logP(o/w) to
logP(cyclohexane/water) by using shake ﬂask method given
in OECD guidelines of Chemical Testing (No. 107 and 117).
The other molecular descriptor logD was calculated using
logD

pH

= logP −log

1+10
∗(pka−pH)

. (2)
logD denotes dissociation constant and logP denotes parti-
tion coeﬃcient.
Both, molecular descriptors (ΔlogP and logD)w e r e
derivedforthestudiedﬂuoroquinolones(norﬂoxacin,cipro-
ﬂoxacin, lomeﬂoxacin, oﬂoxacin, levoﬂoxacin, sparﬂoxacin,
peﬂoxacin, gatiﬂoxacin, and moxiﬂoxacin) and logPC was
determined using Algorithm (1). The derived logPC from
Algorithm (1) was correlated with that obtained from
controlled in vivo experiment in rabbits.
2.5.2.EvaluationofModel2ReportedbyFuandLiang. Model
2 evaluated reported by Fu and Liang [11] was based upon
charge and molecular volume as the molecular descriptors to
predict logPC. Algorithm (3) was reported to predict corneal
permeability for noncongeneric compounds
logPC =− 5.566Q2
H +3 .027QH −0.155QO,N
− 9.413 ×10
−4V −4.278
(3)
wherein logPC denotes permeability coeﬃcient, QH is sum
of the absolute values of net atomic charge of hydrogen
atom, and QO,N is sum of the absolute values of the net
atomic charges of oxygen and nitrogen atoms. V is molecular
volume.
The charge (Q2
H,QH,QO,N) for all ﬂuoroquinolones was
calculatedbyusingGAMESSsoftwareandmolecularvolume
by drug design software developed at Super Computing
Facility, Indian Institute of Technology, New Delhi. Struc-
tures of all ﬂuoroquinolones were drawn HYPERCHEM
version 11.0 and optimized the geometry to lowest energy
state. The net charge on each atom was calculated as the
sum of all atoms present in the particular structure. The
molecular descriptors used in algorithm (3) were derived
for the studied nine ﬂuoroquinolones to predict logPC. The
derived logPC from algorithm (3) was also correlated with in
vivo experimentally obtained logPC.
2.6. Generation of the Novel QSPR Model to Predict In Vivo
Corneal Permeability. A novel QSPR model was generated
using pooled molecular descriptors determined using in
vitro, in vivo, and in silico approaches for ﬂuoroquinolones.
In Vitro Data. Partition coeﬃcient (logP) was determined
using OECD Shake Flask method for chemical testing (No.
107 and 117) using biphasic system of octanol/water at 25◦C
and 37◦C.
In Vivo Data. Permeability coeﬃcients (logPC) were obtai-
ned from controlled in vivo experiment conducted in rabbits
using cassette dosing (N-in-One) approach.
In Silico Data. Diﬀerent molecular descriptors were gener-
ated using softwares like CAChe Scientiﬁc (Fujitsu version
6.1.12.33, Japan), ACD/Chemsketch (Freeware version 10),
ChemDraw and Chem BioDraw Ultra from Cambridge
Soft (trial version), calculator Plugins of Chem Axon’s
Marvin version 5.2.5.1, Chem Axon Ltd. All ﬂuoroquinolone
structures were drawn in respective workspace and standard
molecular mechanics were run before geometry optimiza-
tion. The descriptors like molecular weight, logP,t o p o l o g -
ical polar surface area (TPSA), molar refractivity, number of
“H”-bond donors/acceptor, dipole moment, lowest unoccu-
piedmolecularorbitals(LUMO),highestunoccupiedmolec-
ular orbital (HUMO), GAP, molecular volume, connolly
accessible area, connolly molecular area, principal moment,
dipole moment, molecular weight, wiener index, melting
point, polar surface area, number of rotatable bonds and
molar refractivity, molar volume, polarizibility, parachor,
index of refraction, surface tension, density, monoisotopic
mass, nominal mass, average mass, apKa, and charge on the
each atom, that is, QN,Q O,N ,Q H,Q F and QC were extracted
using diﬀerent kind of softwares.
2.7. Suitability of Newly Developed QSPR Model to Predict
Corneal Permeability of Compounds Other Than Fluoro-
quinolones. To ensure the suitability of newly developed
QSPR model, the congeneric compounds used by Yoshida
and Topliss [10] and Fu and Liang [11] were pooled. All the
congeneric compounds (β-blockers, n = 15) were pooled
and molecular descriptors used in newly developed QSPR
model were extracted. The β-blockers pooled include aceb-
utolol, alprenolol, atenolol, betaxolol, bevantolol, bufuralol,
levobunolol, metoprolol, nadolol, oxprenolol, penbutolol,
pindolol,propanolol,sotalol,andtimolol.ThelogPCderived
using newly developed QSPR model was correlated with
reported logPC for all the β-blockers.
3. Results
3.1. In Vivo Transcorneal Permeation Using Cassette Dosing
Approach. Two diﬀerent HPLC-PDA method were devel-
oped and validated to elute all ﬂuoroquinolones in group AJournal of Biomedicine and Biotechnology 5
Table 2: Gradient mobile phase used during the analysis by HPLC-PDA for ﬂuoroquinolones in group A and group B.
Time (min) Methanol (%) Acetonitrile (%) Buﬀer (20mM) (%) Flow rate (mL/min)
Group A
0.01 0 10 90 1.0
4.00 5 15 85 1.0
10.0 0 40 60 1.0
12.0 0 10 90 1.0
Group B
0.01 10 10 80 1.0
6.00 10 10 80 1.0
8.00 0 50 50 1.0
10.0 10 10 80 1.0
and B. For the analysis of group A (oﬂoxacin, sparﬂoxacin,
peﬂoxacin, and gatiﬂoxacin) the gradient mobile phase
consisted of diﬀerent ratios of methanol, acetonitrile, and
potassiumphosphatebuﬀer(20mM,pH2.5)overtheperiod
of 12min (Table 2). For the analysis of ﬂuoroquinolones
in group B (norﬂoxacin, ciproﬂoxacin, lomeﬂoxacin, lev-
oﬂoxacin, and gatiﬂoxacin) the gradient mobile phase
consisted of diﬀerent ratios of methanol, acetonitrile, and
potassiumphosphatebuﬀer(20mM,pH2.5)overtheperiod
of 10min (Table 2).
The representative chromatograms of all ﬂuoroquino-
lones eluted in group A and group B are shown in Figures
1(a) and 1(b).
The validation parameters regarding the accuracy and
precision were found to be within the allowable limits
according to ICH guidelines for HPLC in bioanalysis. The
meanconcentrationversustimeplotforallﬂuoroquinolones
(group A and B) are shown in Figures 2(a) and 2(b).
The derived pharmacokinetics parameters like Cmax,
Tmax, AUC, logPC at 30min and 240min generated for all
ﬂuoroquinolones are tabulated in Table 3.
3.2. Applicability of Existing Models to Predict Corneal
Permeability for Fluoroquinolones
3.2.1. Evaluation of Model 1 Reported by Yoshida and Topliss.
Both molecular descriptors (ΔlogP and ΔlogD)d e r i v e df o r
ﬂuoroquinolones in algorithm (1) to derive logPC showed a
weak Spearman correlation (0.133) with that obtained from
in vivo experiment (Table 4).
The weak correlation was observed at 30min (r2 =
0.0699) and 240min (r2 = 0.0137). The statistically
insigniﬁcant correlation suggeststhat algorithm (1)i su n a b l e
to appropriately predict corneal permeability for ﬂuoro-
quinolones (Figure 3(a)).
3.2.2. Evaluation of Model 2 Reported by Fu and Liang.
Algorithm (3)r e p o r t e db yF ua n dL i a n g[ 11]w a se m p l o y e d
to derive logPC for all studied ﬂuoroquinolones (Table 4).
A very weak Spearman correlation of 0.134 was observed
between the logPC derived experimentally at both 30min
and 240min with that logPC derived using algorithm
(3)( Figure 3(b)). The statistically insigniﬁcant correlation
suggests that algorithm (3) is unable to appropriately predict
corneal permeability for ﬂuoroquinolones.
3.3. Generation of New QSPR Model for Determination
of In Vivo Corneal Permeability. A total of 72 molecular
descriptors were extracted for all nine topically studied
ﬂuoroquinolones (norﬂoxacin, ciproﬂoxacin, lomeﬂoxacin,
oﬂoxacin, levoﬂoxacin, sparﬂoxacin, peﬂoxacin, gatiﬂoxacin
and moxiﬂoxacin) using in vitro, in vivo, and in silico
approaches. All sets of data were subjected to multilinear
regression (MLR) statistical analysis by Sigma Stat Software
(version 3.5, Germany). For the generation of algorithm
the in vivo data of logPC calculated for absorption phase
(30min) and elimination phase (240min) was used. The
algorithms developed with logP and apKa either with GAP
(algorithms (4)a n d( 5)) and or with TPSA (algorithms (6)
and (7) )e x h i b i t e dg o o dc o r r e l a t i o n
logPC 30 min = 13.972 +

1.529 ∗ logP

−

1.375 ∗apKa

+(1.308 ∗GAP),
R = 0.908 Rsqr = 0.825 Adj Rsqr = 0.720,
(4)
logPC 240 min = 9.946 +

1.368 ∗logP

−

1.429 ∗apKa

+(0.952 ∗GAP)
R = 0.940 Rsqr = 0.883 Adj Rsqr = 0.813,
(5)
whereinlogPCdenoteslogarithmofpermeabilitycoeﬃcient,
logP is partition coeﬃc i e n ta tw a t e r2 5± 1◦C for 30min,
GAP is the diﬀerence in HUMO and LUMO energy levels,
and apKa is acid dissociation constant.6 Journal of Biomedicine and Biotechnology
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Figure 1: (a) Chromatogram of the ﬂuoroquinolones in group A (oﬂoxacin, peﬂoxacin, gatiﬂoxacin, and sparﬂoxacin) eluted in single
run. (b) Chromatogram of ﬂuoroquinolones in group B (levoﬂoxacin, norﬂoxacin, ciproﬂoxacin, lomeﬂoxacin, and moxiﬂoxacin) eluted in
single run.
Algorithms (6)a n d( 7) were developed using logP, TPSA,
and apKa as molecular descriptor at 30min and 240min.
logPC 30 min =− 1.453 +

1.726 ∗logP

−

0.708 ∗apKa

+(0.0104 ∗TPSA)
R = 0.934 Rsqr = 0.872 Adj Rsqr = 0.796,
(6)
logPC 240 min =− 2.726 +

1.439 ∗logP

−

0.672 ∗apKa

+(0.00421 ∗ TPSA)
R = 0.937 Rsqr = 0.877 Adj Rsqr = 0.803,
(7)
whereinlogPCdenoteslogarithmofpermeabilitycoeﬃcient,
logP as partition coeﬃc i e n ta tw a t e r3 6± 1◦C for 5min,Journal of Biomedicine and Biotechnology 7
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Figure 2:(a)Meanconcentration(μg/mL)versustime(min)plotforalltheﬂuoroquinolonesingroupA(oﬂoxacin,peﬂoxacin,gatiﬂoxacin,
andsparﬂoxacin).(b)Meanconcentration(μg/mL)versustime(min)plotforalltheﬂuoroquinolonesingroupB(levoﬂoxacin,norﬂoxacin,
ciproﬂoxacin, lomeﬂoxacin, and moxiﬂoxacin).
Table 3: Pharmacokinetic parameters derived for all ﬂuoroquinolones using in vivo cassette dosing approach in rabbits.
Fluoroquinolones Cmax ± SD (μg/mL) Tmax (min) AUC (μg·hr/mL) logPC (30min) logPC (240min)
Norﬂoxacin 0.456 ± 0.059 60min 2.854 −5.051 −6.382
Ciproﬂoxacin HCl 0.146 ± 0.084 60min 0.507 −5.806 −7.089
Lomeﬂoxacin HCl 0.266 ± 0.046 60min 0.833 −5.519 −6.859
Oﬂoxacin 0.597 ± 0.736 60min 0.930 −5.284 −6.723
Levoﬂoxacin 0.147 ± 0.053 60min 0.311 −5.678 −7.225
Sparﬂoxacin 1.151 ± 0.514 30min 1.770 −4.753 −6.396
Peﬂoxacin mesylate 4.103 ± 1.399 60min 7.225 −4.075 −5.778
Gatiﬂoxacin 0.682 ± 0.904 30min 1.179 −5.006 −6.628
Moxiﬂoxacin 0.594 ± 0.294 30min 1.045 −5.022 −6.664
TPSA as topological polar surface area, apKa is acid disso-
ciation constant.
Figure 4 shows the pictorial representation of newly
developed QSPR model using ﬂuoroquinolone as model
group.
In the four newly developed algorithms (algorithms (4),
(5), (6), and (7)) logP and apKa are common molecular
descriptors, signifying the key descriptors aﬀecting penetra-
tion of ﬂuoroquinolones across the cornea. Algorithms (4),
(5), (6), and (7) showed a positive correlation with logP and
inverse correlation with apKa. TPSA and GAP also showed a
positive correlation with permeability coeﬃcient in all newly
developed algorithms.
3.4. Suitability of New QSPR Model to Predict Corneal
Permeability for Compounds Other Than Fluoroquinolones.
The logPC was generated for β-blockers pooled from Models
1 and 2. Newly developed QSPR model showed a positive
Spearman correlation of 0.831 and 0.887 between the newly
developed algorithms (4)a n d( 5)w i t ha l r e a d yr e p o r t e d
logPC (Figure 5(a)).
A positive Spearman correlation of 0.881 and 0.803
between the logPC generated for β-blockers using newly
developed algorithms (6)a n d( 7) and reported logPC
(Figure 5(b)).
4. Discussion
Conventionally, antimicrobial drugs developed and
approved for systemic infections are extended for ocular
infections. An antimicrobial agent having good corneal
penetration and eﬃcacy is desired in preventing sight
threatening infections. Fluoroquinolones are the commonly
used topical antimicrobial agents in ocular therapeutics.
It is well known that less than 5% of the topically applied
drug penetrates through the cornea. Therefore, there is an
urgent need to understand the constraints exerted by the
eye for the development of an ocular speciﬁc antimicrobial8 Journal of Biomedicine and Biotechnology
Table 4: Determination of various molecular descriptors used in Model 1, and 2 along with permeability coeﬃcient (logPC) derived using
algorithms (1) and (3) for all ﬂuoroquinolones.
Fluoroquinolones ΔlogP (Cyclohexane-Octanol) logD logPC$ QH Q
2
H QO,N Molecular Volume logPC#
Norﬂoxacin 0.051 −0.493 −3.752 0.876 0.767 −2.954 110.375 −5.540
Ciproﬂoxacin HCl −0.358 −0.963 −3.653 0.848 0.719 −2.750 108.000 −5.388
Lomeﬂoxacin HCl 1.113 0.182 −4.086 0.847 0.717 −2.577 113.635 −5.412
Oﬂoxacin 0.759 −0.290 −4.009 0.461 0.212 −2.567 121.375 −3.781
Levoﬂoxacin 0.734 −0.186 −3.985 0.461 0.212 −2.567 121.375 −3.781
Sparﬂoxacin 1.025 0.174 −4.052 1.648 2.715 −3.704 125.875 −13.946
Peﬂoxacin mesylate 0.709 −0.095 −3.962 0.472 0.223 −2.321 113.375 −3.836
Gatiﬂoxacin 0.526 −0.399 −3.931 0.815 0.663 −2.697 123.125 −5.203
Moxiﬂoxacin 0.908 −0.272 −4.067 0.821 0.674 −2.774 130.750 −5.239
$logPC derived from algorithm (1)f r o mM o d e l1 ;#logPC derived from algorithm (3)f r o mM o d e l2 .
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Figure 3:(a)Permeabilitycoeﬃcient(logPC)derivedusingalgorithm(1)versuspermeabilitycoeﬃcient(logPC)derivedfrominvivostudy.
(b) Graph between permeability coeﬃcient(logPC)derivedusingalgorithm(3) versus permeability coeﬃcient (logPC) derived from in vivo
study.
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Figure 5: (a) Correlation between permeability coeﬃcient (logPC) reported in literature for β-blockers versus permeability coeﬃcient
(logPC) derived values using newly developed algorithms (4) and (5)f o rβ-blockers (n = 15). (b) Correlation between the permeability
coeﬃcient (logPC) reported in the literature for β-blockers versus permeability coeﬃcient (logPC) derived values from newly developed
algorithms (6) and (7)f o rβ-blockers (n = 15).
agent [3]. In present study, QSPR approach has been used
to comprehend the physicochemical factors aﬀecting corneal
permeability for topically applied drugs. An attempt was
made in present study to evaluate the suitability of in
silico models in predicting the in vivo corneal permeability
of ﬂuoroquinolones. To ascertain the obtained results,
various molecular descriptors were extracted from diﬀerent
softwares. Additionally, in vivo corneal permeability was
determined in rabbits employing cassette dosing approach,
a high throughput pharmacokinetic screening technique
which has been exploited for various indication [12–14].
So far this approach has been limited to in vitro and few in
vivo models in ophthalmic drug research [15–17]. However,
for the ﬁrst time, we employed cassette dosing technique
to study the in vivo pharmacokinetic proﬁle of topically
applied ﬂuoroquinolones and to derive a controlled in vivo
permeability coeﬃcient
Nine topically used ﬂuoroquinolones were dissolved
in two cassettes: group A with four and group B with
ﬁve ﬂuoroquinolones. Being weakly basic in nature ﬂuoro-
quinolones are expected to exist in ionized form at pH 4.5.
Therefore, pH of both formulations was maintained at 5.0
and osmolarity as 307mOsM/L using boric acid. Boric acid
(1.9%) has been reported to be an appropriate vehicle for
the preparation of ophthalmic solutions having basic nature
[18]. In addition, it is reported to avoid any interaction
between ﬂuoroquinolones and di/monovalent cations [19].
Intheliteraturetwomodelshavebeenreportedtopredict
the corneal permeability. The ﬁrst model was reported by
Yoshida and Topliss [10]b a s e du p o nΔlogP and logD
as molecular descriptors. In this model, ΔlogP mainly
correlates with the solute hydrogen bonding acidity or
basicity and to lesser extend dipolarity or polarizability.
The second model was reported by Fu and Liang [11]w a s
based upon charge and molecular volume as the molecular
descriptors. Unfortunately, both the earlier reported models
wereunsuitabletopredictinvivocornealpermeabilityofﬂu-
oroquinolones. A poor correlation between the permeability
coeﬃcient derived using reported models [10, 11] with that
derived from present in vivo study was observed. This may
be due to the fact that reported models were developed
based upon permeability coeﬃcients (logPC) pooled from
variousinvitrostudies.Theinvitroconditionsdenoteastatic
system rather than actual dynamic conditions which exists in
eye. Moreover, the involvement of various drug transporters
and precorneal factors is not considered in such studies
and are also believed to have major role. Thus, reported
models [10, 11]b a s e du p o nin vitro corneal permeability
a r eu n a b l et oc o r r e l a t ew i t hin vivo corneal permeability for
ﬂuoroquinolones. Therefore, a new in silico model based
upon in vivo permeability coeﬃcient data was felt desirable.
Also the in silico model should be able to correlate with
parameters like ionizing property, transporter susceptibility,
and lipophilicity, precorneal pH of compound.
A novel QSPR model was developed based upon in vivo
corneal permeability along with molecular descriptors like
logP, apKa, GAP, and TPSA. All the molecular descriptors
used are known to aﬀect the corneal permeability. Civiale
and coworkers [20] also reported that corneal permeation
process can be conﬁned at the ocular epithelium layer.
Studies have been reported that in corneal epithelium
the drugs are expected to undergo transcellular pathway10 Journal of Biomedicine and Biotechnology
[21, 22]. Whereas the penetrating molecules are expected in
hydrophilic form as a result of pH or after hydrolysis due to
enzymes (by prodrug attempt) to cross hydrophilic stroma.
Thus, the hydrogen bonding aﬃnity plays a vital role in
transcorneal permeation.
The dissociation constant (pKa) of the compound
determines the HLB (hydrophilic/lipophilic balance) in the
cornea. Thus, pKa provides a correlation with the corneal
permeability of topically applied drug. Based upon the
presenceofionizable/functionalgroupsmoleculescanposses
more than one pKa. An assumption was made in the newly
developed QSPR model that for ﬂuoroquinolones apKa has
more implication on the availability of the species. Other
studies also report that corneal penetration can be enhanced
by selecting the drug molecule with appropriate pKa and
oﬀeringoptimallipidsolubility[23,24].Ingeneral,adjusting
pH so that a drug is mostly in the unionized form increases
its lipophilicity and thus, its transcellular permeability, and
ocular absorption.
Another molecular descriptor GAP, which is diﬀerence
in energy between EHUMO and ELUMO, has also reported to
be an important stability index and related to transporters
susceptibility [25]. The EHUMO measures the electron donat-
ing and ELUMO measures electron accepting property of the
molecule. A HUMO and LUMO energy separation has been
usedasaconventionalmeasureofkineticstabilityforvarious
π-electron systems. A large GAP has been reported to relate
with high stability for a molecule in the sense of its lower
sensitivity in chemical reaction [26, 27].
TPSAisdeﬁnedasthesumofsurfacesofpolaratomsina
molecule and known to correlate with transporter suscepti-
b i l i t y .T P S Am a k e su s eo ff u n c t i o n a lg r o u pb a s e du p o nl a r g e
database of structures that avoids the need to calculate ligand
3D structure or to decide which one is relevant biological
conformation. Therefore, in this analysis, TPSA has been
taken into account to deﬁne the transcorneal penetration
of congeneric compounds. Fernandes and coworkers [28]
suggested that compounds with high TPSA are transported,
whilethose with low TPSAare not. Moreover, conjugationto
compounds like GSH is reported to increase the TPSA values
as a favoring transport mechanism. A strong correlation
between TPSA and transport properties has been observed
in present study. The algorithm developed either with
TPSA or GAP proved to predict the intraocular penetration
appropriately as compared with other molecular descriptors
tried with highest degree of correlation (r2 > 0.9)
The applicability of the newly developed algorithms (4),
(5), (6), and (7) on other sets of compounds apart from
ﬂuoroquinolones was also tested. The congeneric compound
trial sets taken for this analysis belong to the category of β-
blockers where the ioniziability and pH-dependent changes
in the lipophilicity are not much of concern. Their structures
predominately lacking primary amino groups or carboxylic
acids (except atenolol having primary amine) therefore, pH-
induced changes are not expected to play a major role. This
study further evaluated the applicability of the developed
algorithm on the noncongeneric compounds using similar
training sets. However, the corneal predictability was found
to be insigniﬁcant. The newly developed in silico model is
based upon in vivo data and hence may predict corneal
permeability for congeneric compounds other than ﬂuoro-
quinolone more appropriately.
5. Conclusions
The previously reported algorithms based on in vitro data
failed to predict in vivo corneal permeability for ﬂuoro-
quinolones. A novel QSPR model consisting of four new
algorithms were developed using GAP, TPSA, logP, and
apKa as molecular descriptors to predict in vivo corneal
permeability. The hypothesis generated showed high degree
of applicability to predict transcorneal penetration as it was
based upon the in vivo corneal permeability coeﬃcients data.
Moreover, the developed model was also found to predict
corneal permeability of the congeneric β-blockers (r2 > 0.6)
reported in the literature. Further studies are in progress
to evaluate its utility in large number of other congeneric
compounds.
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